These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19255315)

  • 1. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.
    Dilts DM; Sandler AB; Cheng SK; Crites JS; Ferranti LB; Wu AY; Finnigan S; Friedman S; Mooney M; Abrams J
    J Clin Oncol; 2009 Apr; 27(11):1761-6. PubMed ID: 19255315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
    Dilts DM; Sandler AB; Baker M; Cheng SK; George SL; Karas KS; McGuire S; Menon GS; Reusch J; Sawyer D; Scoggins M; Wu A; Zhou K; Schilsky RL;
    J Clin Oncol; 2006 Oct; 24(28):4553-7. PubMed ID: 17008694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group.
    Dilts DM; Sandler A; Cheng S; Crites J; Ferranti L; Wu A; Gray R; MacDonald J; Marinucci D; Comis R
    Clin Cancer Res; 2008 Jun; 14(11):3427-33. PubMed ID: 18519773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III clinical trial development: a process of chutes and ladders.
    Dilts DM; Cheng SK; Crites JS; Sandler AB; Doroshow JH
    Clin Cancer Res; 2010 Nov; 16(22):5381-9. PubMed ID: 21062928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and benefits of the national cancer institute central institutional review board.
    Wagner TH; Murray C; Goldberg J; Adler JM; Abrams J
    J Clin Oncol; 2010 Feb; 28(4):662-6. PubMed ID: 19841324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.
    Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA
    Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to institutional review board approval with local versus central review in a multicenter pragmatic trial.
    Neuman MD; Gaskins LJ; Ziolek T;
    Clin Trials; 2018 Feb; 15(1):107-111. PubMed ID: 28982261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: industry collaborations in new agent development.
    Ansher SS; Scharf R;
    Ann N Y Acad Sci; 2001 Dec; 949():333-40. PubMed ID: 11795372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
    Abrams JS; Mooney MM; Zwiebel JA; Korn EL; Friedman SH; Finnigan SR; Schettino PR; Denicoff AM; Kruhm MG; Montello M; Misra RR; Ansher SS; DiPiazza KJ; Souhan EM; Wickerham DL; Giantonio BJ; O'Donnell RT; Sullivan DM; Soto NI; Fleming GF; Prindiville SA; Petryshyn RA; Hautala JA; Grad O; Zuckerman BL; Meyer RM; Yao JC; Baker LA; Buckner JC; Hortobagyi GN; Doroshow JH
    J Natl Cancer Inst; 2013 Jul; 105(13):954-9. PubMed ID: 23776198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines.
    Ning N; Yan J; Dietrich MF; Xie XJ; Gerber DE
    J Oncol Pract; 2017 Dec; 13(12):e982-e991. PubMed ID: 29019706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic.
    Wang-Gillam A; Williams K; Novello S; Gao F; Scagliotti GV; Govindan R
    J Clin Oncol; 2010 Aug; 28(24):3803-7. PubMed ID: 20644091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.
    Dilts DM; Sandler AB
    J Clin Oncol; 2006 Oct; 24(28):4545-52. PubMed ID: 17008693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central institutional review board review for an academic trial network.
    Kaufmann P; O'Rourke PP
    Acad Med; 2015 Mar; 90(3):321-3. PubMed ID: 25406606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
    Reuss JE; Stern D; Foster JC; Ramaswami R; Lurain K; Chen HX; Streicher H; Kem R; Little RF; Sharon E
    JAMA Netw Open; 2020 Dec; 3(12):e2027110. PubMed ID: 33258905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
    Gadgeel SM; Ivy P; Chen W; Mauer J; Smith D; Lorusso P
    Clin Lung Cancer; 2011 Jul; 12(4):218-23. PubMed ID: 21726820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meeting the Challenge: The National Cancer Institute's Central Institutional Review Board for Multi-Site Research.
    Massett HA; Hampp SL; Goldberg JL; Mooney M; Parreco LK; Minasian L; Montello M; Mishkin GE; Davis C; Abrams JS
    J Clin Oncol; 2018 Mar; 36(8):819-824. PubMed ID: 29384720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficiency of single institutional review board review in National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network-initiated clinical trials.
    Diamond MP; Eisenberg E; Huang H; Coutifaris C; Legro RS; Hansen KR; Steiner AZ; Cedars M; Barnhart K; Ziolek T; Thomas TR; Maurer K; Krawetz SA; Wild RA; Trussell JC; Santoro N; Zhang H;
    Clin Trials; 2019 Feb; 16(1):3-10. PubMed ID: 30354458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.